Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells

Cell Death and Differentiation

Volumn 18, Issue 1, 2011, Pages 16-25

  Li, Q Q ^a   Chen, Z Q ^b   Cao, X X ^a   Xu, J D ^a   Xu, J W ^a   Chen, Y Y ^a   Wang, W J ^b   Chen, Q ^a   Tang, F ^b   Liu, X P ^a   Xu, Z D ^b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

amphiregulin EGFR; chemotherapy; EMT; miR 448; NF B; SATB1

Indexed keywords

AMPHIREGULIN; BINDING PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; MICRORNA; MICRORNA 488; MITOGEN ACTIVATED PROTEIN KINASE; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 1; TWIST1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CARCINOMA CELL; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEEDBACK SYSTEM; GENE REPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA ISOLATION;

ANTIBIOTICS, ANTINEOPLASTIC; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DOXORUBICIN; EPITHELIAL-MESENCHYMAL TRANSITION; FEEDBACK, PHYSIOLOGICAL; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX ATTACHMENT REGION BINDING PROTEINS; MICRORNAS; NF-KAPPA B; NUCLEAR PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TWIST TRANSCRIPTION FACTOR;

EID: 78650179541     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.103     Document Type: Article

References (40)

1. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993; 85: 632-639.
2. Yang JM, Medina GY, Vassil DJ, Liao AD, Hait J. Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. Biochem Biophys Res Commun 1999; 266: 167-173.
3. Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H et al. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 2008; 68: 516-520.
4. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005; 17: 1-11.
5. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-454.
6. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004; 48: 365-375.
7. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005; 132: 3151-3161.
8. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005; 8: 197-199.
9. Yang J, Mani SA, Weinberg RA. Exploring a new Twist on tumor metastasis. Cancer Res. 2006; 66: 4549-4552.
10. Mironchik Y, Winnard Jr PT, Vesuna F, Kato Y, Wildes F, Pathak AP et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 2005; 65: 10801-10809.
11. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006; 118: 290-301.
12. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007; 31: 277-283.
13. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009; 15: 2657-2665.
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
15. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435: 828-833.
16. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006; 124: 1169-1181.
17. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of microRNA genes miR-15 and miR-16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci 2002; 99: 15524-15529.
18. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64: 3753-3756.
19. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. RAS is regulated by the let-7 microRNA family. Cell. 2005; 120: 635-647.
20. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull. 2006; 29: 903-906.
21. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9: 189-198.
22. Zavadil J, Narasimhan M, Blumenberg M, Schneider RJ. Transforming growth factor-beta and microRNA: mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs. 2007; 185: 157-161.
23. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9: 582-589.
24. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10: 593-601.
25. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283: 14910-14914.
26. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008; 22: 894-907.
27. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF et al. A doublenegative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008; 68: 7846-7854.
28. Christoffersen NR, Silahtaroglu A, Orom UA, Kauppinen S, Lund AH. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA. 2007; 13: 1172-1178.
29. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008; 452: 187-193.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133: 704-715.
31. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008; 454: 56-61.
32. Funatomi H, Itakura J, Ishiwata T, Pastan I, Thompson SA, Johnson GR et al. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer. 1997; 72: 512-517.
33. Castillo J, Erroba E, Perugorŕ?a MJ, Santamaŕ?a M, Lee DC, Prieto J et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res. 2008; 66: 6129-6138.
34. Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, Ethier SP. Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells. Mol Cancer Res. 2007; 5: 847-861.
35. Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, Ethier SP. Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon. J Cell Biol. 1992; 118: 741-751.
36. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005; 65: 9455-9462.
37. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005; 11: 8686-8698.
38. Del Castillo G, Murillo MM, Alvarez-Barrientos A, Bertran E, Fernández M, Sánchez A et al. Autocrine production of TGF-beta confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: Role of EGF receptor ligands. Exp Cell Res 2006; 312: 2860-2871.
39. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114: 569-581.
40. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. Biol Chem 2001; 276: 7614-7620.